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FOREWORD
I am delighted to welcome the publication of the ABCD Diabetes Technology Network UK 
Insulin Pump Best Practice Guide. Insulin pump use in Type 1 diabetes is associated with 
improved quality of life and glycaemic control in addition to reductions in hypoglycaemia and 
is a fundamental part of the Type 1 diabetes care paradigm. NICE provides clear guidance on 
the use of insulin pumps and following the publication of NICE TA 151 in 2008 the uptake of 
insulin pumps in the UK improved.
 
However more recently this uptake has plateaued and we need to ensure we-as a nation- do 
not fall behind others as well as enable access to appropriate technology where warranted. The 
National Diabetes Insulin Pump Audit demonstrates lower HbA1c levels in insulin pump users 
vs non  users; 20% more people with Type 1 diabetes on an insulin pump achieve an HBA1c < 58 
mmol/mol (7.5%).  Unfortunately in the UK there is too much variability in the provision 
of pump therapy, with some geographical locations with an uptake of >30% of their Type 1 
diabetes population and some at <5%. This variation needs to be addressed if we are to improve 
outcomes in Type 1 diabetes and this publication will support that.
 
A key barrier to accessing insulin pump therapy, identified in the 2012 insulin pump 
service level audit, was staff training which has continued to be an area of concern. The 
development of this best practice guide which provides clear direction in a number of areas 
including pump optimisation, selection of candidates for pump therapy as well as indication 
for withdrawal will go a long way in equipping diabetes specialist teams with knowledge 
required to deliver pump services.
 
Many thanks to the authors of this guide who between them deliver care for over 7000 current 
insulin pump users in the UK.
Yours sincerely
Partha Kar
Consultant in Diabetes & Endocrinology at Portsmouth Hospitals NHS Trust
Associate National Clinical Director of Diabetes with NHS England
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OBJECTIVES
This document aims to provide healthcare professionals with UK expert consensus on the best practice for 
managing and optimising CSII.
Introduction 
Continuous subcutaneous insulin infusion (CSII or 
insulin pump therapy) is a mode of delivering intensive 
insulin therapy, which usually leads to improved glucose 
control and reduced hypoglycaemia. 
What is CSII?
CSII employs a battery operated, portable, programmable 
pump to continuously deliver rapid-acting insulin via 
an infusion set inserted subcutaneously. The basal 
insulin infusion rate can be varied at least hourly and 
can be temporarily adjusted upwards or downwards 
by a fixed percentage. Several different basal rate 
profiles can be stored for use in different situations. 
Bolus doses can be given with meals as an immediate 
bolus, an extended bolus or a combination of the two. 
Most pumps incorporate bolus calculators which take 
account of insulin still active from previous boluses to 
provide advice to the user as to the bolus dose needed. 
CSII is used as a component of self-management of Type 
1 diabetes supported by the Diabetes Specialist Team. 
This team should at a minimum include a pump-trained 
consultant diabetologist, diabetes specialist nurse and 
dietitian. The decision to start insulin pump therapy 
should be made by the pump multidisciplinary team.
What is the evidence that CSII is effective?
There is good evidence that CSII can reduce both HbA1c 
and hypoglycaemia frequency when used in place of 
MDI for intensive insulin therapy (Pickup and Sutton 
2008). Additionally, CSII can reduce glycaemic variability 
and improve aspects of quality of life, particularly in 
relation to diet and physical activity (REPOSE study 
group 2017, Hoogma et al. 2006). Recent evidence has 
demonstrated an association between use of CSII and 
reduced mortality (Steineck et al. 2015). 
A 2008 meta-analysis reported that severe hypoglycaemia 
was reduced by a ratio of 2.89 in RCTs and 4.34 for before/
after studies. The reduction was greatest in those with 
initial high rates of hypoglycaemia. The mean HbA1c 
reduction was 0.21% (2.3 mmol/mol) in RCTs and 0.72% (7.9 
mmol/mol) in before/after studies. Similarly, the greatest 
reduction in HbA1c was seen in those with the highest 
initial HbA1c (Pickup and Sutton 2008).
CSII is recommended by NICE Technology Appraisal 
151 (TA151) as a treatment option for people with Type 
1 diabetes who meet the clinical criteria specified in 
the TA and for whom it is clinically appropriate. CSII 
should be offered where glycaemic control issues persist 
despite optimised multiple daily injection therapy (MDI) 
which has been supported by a structured education 
programme fulfilling the criteria laid out in NICE 
clinical guideline NG17.
Integrated sensor augmented pump (SAP) therapy 
systems combine continuous glucose monitoring (CGM) 
with continuous subcutaneous insulin infusion and 
are intended to further improve glycaemic control and 
quality of life for people with Type 1 diabetes. Evidence 
suggests average HbA1c improvements of approximately 
0.5% (5.5 mmol/mol) can be achieved with the addition of 
CGM to CSII when the CGM component is in use at least 
60-70% of the time (Batellino et al. 2012, Bergenstal et al. 
2011, Raccah et al. 2009)
There is more limited evidence for reduction in 
hypoglycaemia frequency with SAP (Choudhary et 
al. 2013, Ly et al 2013). However NICE clinical guideline 
NG17 has stressed the importance of alarmed CGM 
for protecting those with problematic hypoglycaemia. 
SAP systems which stop insulin delivery when 
hypoglycaemia occurs, or is predicted to occur, have 
been shown to significantly reduce the frequency and 
severity of hypoglycaemia (Choudhary et al. 2016).
Whilst CSII has evident benefits and modern insulin 
pumps are very safe, structured patient education 
at initiation of pump therapy in addition to ongoing 
support and refresher education to enable effective use 
of CSII are imperative to ensure that glycaemic control 
is optimised, and that the user is able to identify any 
failure of pump insulin delivery and take appropriate 
action to maintain safe glycaemic control.
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ENGLAND
The percentage of adults with Type 
1 diabetes on pumps in England has 
increased from 6% in 2012 to 15% 
in the 2016 National Diabetes Pump 
audit. However, with only ~40% 
of centres in England participating 
in the audit it is possible that this 
number is an overestimate. While 
the overall percentage on pumps 
is higher in England than the other 
4 nations, there is huge variation 
between centres with some providing 
the technology to <5% while other 
centres have in excess of 30% on 
insulin pumps. DTN-UK is actively 
working with NHS England, NHS 
Digital and ABCD to investigate and 
address these variations in care.
SCOTLAND
In Scotland just over 11% of individuals with Type 1 diabetes are on insulin pump therapy. This equates to 
approximately 35% of under 18s and 9% of over 18s. There is a commitment from Scottish government to ensure 
appropriate access to technology to improve diabetes care and £10M has been secured over the lifetime of this 
parliament to increase access to insulin pump therapy and establish continuous glucose monitoring services across 
Scotland. Challenges remain around timely access to structured education and ensuring staff are skilled in the 
use of these technologies. The appointment of a national co-ordinator to support clinical teams to upskill in these 
technologies will help ensure teams have the appropriate skill set to support individuals to manage their diabetes.   
WALES
In Wales NICE TA151 applies and 
therefore funding for insulin pumps 
should be mandatory. Currently 6% 
of adults with Type 1 diabetes are 
on insulin pump therapy but, again, 
there is great variation in uptake 
between centres. As part of the 
Wales Diabetes Delivery Plan the 
Welsh Government have identified 
CSII therapy as one of its core 
priorities to improve the uptake, 
decrease the inequalities to access 
and also ensure that services that are 
delivered are consistent and safe.   
NORTHERN IRELAND
In Northern Ireland 10% of 
adults with Type 1 diabetes 
are on insulin pump therapy. 
Barriers to the uptake of 
insulin pump therapy include 
the availability of recurrent 
funding for devices and staff 
time to support optimal use 
of pump therapy. Northern 
Ireland has now established 
a Diabetes Network inclusive 
of a Technologies Subgroup 
to address these challenges.
Access to CSII across the four nations  
The effectiveness of CSII is well established. However, CSII uptake in the UK continues to lag behind the USA and 
other European countries. Below is a summary of uptake in each of the four nations:
A recurrent theme which limits access across all 4 nations is health care professional time and training (White 
et al. 2014). As such, this guide has been developed with the aim of sharing best practice from across the UK to 
support those who deliver, or would like to deliver, insulin pump services. A multidisciplinary team of healthcare 
professionals with a wealth of expertise in insulin pumps, responsible for providing care for over 7000 insulin 
pump users, have provided input into this guide. It is our hope that by providing clear clinical and service pathways 
that this document will support staff to deliver safe, effective, high quality insulin pump services. 
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Indications for CSII 
The National Institute for Health and Clinical Care 
Excellence (NICE) has published clear guidance on the use 
of continuous subcutaneous insulin infusion for adults 
with diabetes: Technology Appraisal Guidance 151:
1. Continuous subcutaneous insulin infusion (CSII 
or ‘insulin pump’) therapy is recommended as a 
treatment option for adults and children 12 years and 
older with Type 1 diabetes mellitus provided that:
Attempts to achieve target haemoglobin A1c (HbA1c) 
levels with multiple daily injections (MDIs) result in 
the person experiencing disabling hypoglycaemia. For 
the purpose of this guidance, disabling hypoglycaemia 
is defined as the repeated and unpredictable 
occurrence of hypoglycaemia that results in persistent 
anxiety about recurrence and is associated with a 
significant adverse effect on quality of life
or
HbA1c levels have remained high (that is, at 
69 mmol/mol (8.5%) or above) on MDI therapy 
(including, if appropriate, the use of long-acting 
insulin analogues) despite a high level of care.
2. It is recommended that CSII therapy be initiated 
only by a trained specialist team, which should 
normally be comprised of a physician with a 
specialist interest in insulin pump therapy, a 
diabetes specialist nurse and a dietitian. Specialist 
teams should provide structured education 
programmes and advice on diet, lifestyle and 
exercise appropriate for people using CSII.
3. Following initiation in adults and children 12 years 
and older, CSII therapy should only be continued if 
it results in a sustained improvement in glycaemic 
control, evidenced by a fall in HbA1c levels, or a 
sustained decrease in the frequency and severity 
of hypoglycaemic episodes. Appropriate targets for 
such improvements should be set by the responsible 
physician, in discussion with the person receiving 
the treatment or their carer.
4. CSII therapy is not recommended for the treatment 
of people with Type 2 diabetes mellitus, at present.
High level of care, as described in NICE TA151 includes:
• A high degree of motivation, commitment  
and competence; 
• Estimating CHO consumption throughout every day
• Delivering multiple daily injections of insulin  
• Regular glucose self-monitoring (≥4 times /per day)
NICE also recommends insulin pump therapy for use 
in pregnancy (NG3) and in the management of diabetic 
gastroparesis (NG17) (Sharma et al. 2011). 
Other indications
Other indications for pump therapy, with anecdotal 
evidence of benefit are: 
• Diabetic neuropathy, painful peripheral and 
autonomic with orthostatic hypotension (Boulton et 
al. 1982)
• Insulin allergy (Pratt E et al. 2001)
• Needle phobia
• Type 2 diabetes with high insulin requirements who are 
not achieving optimal glucose control despite insulin 
doses titrated to over 1.0 units / kg (Aronson et al. 2014)
BEST PRACTICE GUIDE
08 CLINICAL GUIDELINE 
BEST PRACTICE GUIDE
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) 
 Advantages of pumps over MDI  Disadvantages of pumps over MDI
Fewer needle injections
• No need to inject every time insulin delivery is required
Constant attachment to pump
• Must be worn all the time, including when asleep
• Constant visibility and reminder of diabetes
• Can affect perceived body image
Insulin delivery can be conveniently varied so allowing 
more flexibility
• Basal rates can be varied and programmed to match 
activity, shift work, changing requirements (eg pregnancy, 
hormonal changes, growth spurts, illness, travelling)
• Bolus can be delivered over a varied time to help with other 
conditions eg malabsorption, gastroparesis or dealing with 
particular foods eg pizza
• Temporary suspension or reduction of insulin delivery 
(activity and hypoglycaemia)
• Allows pre-programming of insulin to deliver variable 
amounts insulin without constant input (e.g. whilst 
asleep or working)
• The greater flexibility in insulin delivery and reduced 
variability in glucose levels can enhance quality of life
No long-acting insulin depot
• Risk of rapid diabetic ketoacidosis development if 
technical failure or interruption in pump insulin delivery
• Pumps should only be disconnected for short periods (eg 
swimming)
Complicated set up - infusion set changes
• Set changes are complicated compared to injections 
and infusion sets and cannulas need to be changed 
every 2-3 days
Small insulin doses
• Deliver tiny doses (0.05-0.1 units) versus 0.5 -1 units 
from an insulin pen/syringe (useful for insulin-sensitive 
and young people)
Infusion set problems
• Improper priming, air bubbles, tubing breaks and cannula 
kinks or slippages can interrupt delivery of insulin
Overcome variations in insulin absorption
• Long-acting insulin can be absorbed differently in 
different people. Delivering programmed basal rates 
tailored to individual needs may overcome this problem, 
with the low volume of rapid-acting insulin at the 
infusion site resulting in a more consistent, reliable 
insulin absorption and hence circulating insulin profile 
(Bruntomesso et al. 2008)
Infusion site problems 
• Uncommon but risk of skin infections
Less snacks
• Tailored insulin delivery and reductions in insulin delivery 
during activity reduces the need for snacking
Increased education and training needed
• Requires higher level of education, understanding and 
motivation to get best use of pump and avoid problems
Improved patient experience and satisfaction
• Improved self-management
• Technology can motivate and improve engagement
Increased health care provider training needed
• Health care providers need to have adequate knowledge 
and clinical systems in place to support pump therapy
Better integration with technology
• Newer pumps can link with other technology such as 
meters, continuous glucose monitors, bolus advisors and 
diabetes information management systems
Expense
• Pump costs as well as running costs (infusion sets, 
cannulas, batteries, accessories) are significantly more 
expensive than standard injections
Advantages and disadvantages of CSII 
When offering CSII therapy it is important that consideration is given to the advantages and disadvantages as 
highlighted in table 1 (adapted from Hussain & Oliver: Insulin Pumps and Continuous Glucose Monitoring Made 
Easy, 1e, 2016, Elsevier Ltd)
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Complications of CSII
User feedback on CSII has revealed some useful insights. 
In a survey of 92 insulin pump users with median 
duration of 3.3 years of CSII the following complications 
were described (Pickup at al. 2014)
• Infusion set kinking 64%, 12% frequent*
• Infusion set blockage 54%, 10% frequent*
• Lipohypertrophy 26% 
• Site infection 17%
• 48% reported any pump malfunction, with 26% 
reporting a pump stop/no delivery
*frequent = > 5/year or > 10 for duration of CSII (median 3.3 years)
Any pump malfunction which results in hyperglycaemia 
carries a risk of metabolic decompensation. The pump 
only contains rapid acting insulin and if delivery is 
interrupted for any reason, hyperglycaemia will result. 
If this is not detected and acted on appropriately then 
ketosis progressing to DKA will result. 
Pump failure rates of 16-17 per 100 patient years have 
been reported, with just under 10% resulting in hospital 
admission due to metabolic decompensation (Ross et al 
2016). Accidental damage to pumps accounted for just 
under 30% of pump failures. The median pump 'life 
expectancy' is just under 3 years (Rabbone et al 2017). 
An ADA/EASD diabetes technology working group 
have made a statement on the safety of insulin pump 
therapy with recommendations for increasing safety 
(Heinemann et al 2015).
Reasons for CSII discontinuation
In the T1D Exchange registry 3% of pump users 
discontinued CSII within a year (Wong et al 2017). The 
reasons for discontinuation were:
• Problems with insertion/adhesive 60%
• Pump interfered with sports activities 42%
• Pump uncomfortable to wear 38%
• Pump interfered with intimacy 34%
• Problems with pump working properly 28%
• Problems with high blood glucose levels when using 
pump 28%
Data from a large UK pump service suggested that 
pump therapy was discontinued in 5% of users either 
due to lack of clinical benefit, technical issues, safety 
concerns or user choice (Beato-Vibora et al 2015). 
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Selection for CSII
To achieve optimal use of CSII, people with diabetes 
should be assessed for their suitability via a structured 
process involving the MDT. The following characteristics 
should be considered as part of this assessment:
1. Education, understanding and implementation 
of the principles of intensive insulin 
therapy (carbohydrate counting, pre-meal 
injections, MDI ≥ 3 injections / day, ≥ 4 
glucose measurements / day [SMBG or flash / 
continuous glucose monitoring])
2. Motivation to pursue CSII therapy and improve 
diabetes control 
3. Engagement with diabetes services 
4. Realistic expectations of CSII and clearly agreed 
individual expectations and targets
5. Absence of psychological factors that may 
impair safe CSII use (e.g., psychosis, severe 
anxiety, or severe depression). However, some 
psychological issues such as depression due to 
disease burden from hypoglycaemia or poor 
control may actually respond well to CSII and 
there is evidence that CSII can be safely used in 
this patient cohort (Rodrigues et al 2005)
6. Cognitive, visual and physical impairments 
may require a care partner to be co-trained in 
pump therapy, and should ideally be managed at 
more experienced centres, but should not be a 
contraindication to pump therapy. 
The MDT should continue to support people with 
diabetes who are unable to proceed with pump therapy 
in other ways e.g. through education, improved 
engagement or optimisation of their diabetes 
treatment to achieve targets or become candidates for 
CSII in the future. 
Pump initiation pathway (Figure 1)
Type 1 diabetes teams should be encouraged to discuss 
the option of CSII with all people with diabetes who 
meet the NICE criteria for CSII. If CSII is an option the 
individual would like to pursue, the following pump 
therapy pathway describes the steps towards approval 
and initiation (Figure1) undertaken by the CSII MDT. 
MDT assessment 
The decision to initiate insulin pump therapy should 
only be made following agreement between the 
multidisciplinary insulin pump team and person with 
diabetes or their carer. The person with diabetes should 
have the opportunity to meet with the CSII trained 
diabetes educators to discuss the pros and cons of CSII 
and review the choice of available CSII devices used within 
the service so they are able to make an informed decision 
about which model best meets their needs. Teams should 
be reassured that in clinical practice, the model of pump 
is unlikely to impact on clinical outcomes so personal user 
choice is paramount (Leelarathna et al. 2017).
The team should agree with the user what the goals of 
therapy are (e.g. reduction in HbA1c and/or hypoglycaemia). 
These should be clearly documented in the notes. 
Saline starts?
It is important to ensure there is adequate pre-pump 
education prior to initiating pump therapy. Saline starts 
are not routine practice in all adult centres. However, 
some teams may prefer insulin pump saline starts to 
allow individuals to familiarise themselves with the 
workings of the pump before starting to infuse insulin.
CSII Initiation
As far as possible, insulin pump therapy should be 
commenced at the start of the week. This is to ensure 
that the user has access to clinical support for the 
rest of the week. The diabetes team needs to ensure 
availability to respond quickly if contacted within the 
two week period following initiation. 
We recommend:
1. CSII is commenced ideally in groups of 2-5 to 
maximize resources safely.
2. At the point of CSII initiation the team should 
record diabetes distress scale, hypoglycaemia 
awareness (Gold or Clarke) questionnaire and HbA1c 
to facilitate the longitudinal assessment of objective 
outcomes of pump therapy.
3. Users should be advised of the need to monitor glucose 
levels at least 4/day and keep in daily email or telephone 
contact with the team for the duration of the week.
STARTING PUMP THERAPY
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Insulin pump assessment guideline
All reasonable attempts to optimise glycaemic control on standard injection 
therapy and person with diabetes ready for an insulin pump?
• On basal bolus analogue insulin regimen.
• SMBG ≥ 4 X daily, carbohydrate counting and flexible insulin dosing.
• Attended structured education for above.
Psychological or coping issues that may 
impair safe/ effective use of pump?
Refer for clinical psychology 
assessment before considering pump.
Consider ophthalmology assessment 
or advice before starting pump.
Check coeliac screen. If positive 
consider deferring pump until coeliac 
confirmed/ excluded and established 
on gluten free diet if appropriate.
Active proliferative diabetic 
retinopathy?
Trial of insulin pump
Recent negative coeliac screen, or if 
coeliac established on gluten free diet?
Are criteria for an insulin pump fulfilled? Y/N
NICE: Despite optimised MDI therapy any of: 
 © Attempts to achieve target HbA1c result in 
disabling hypoglycaemia 
or
 © HbA1c levels have remained at 69 mmol/
mol or above
Niche criteria: 
(some may need exceptional funding)
 © Pregnancy
 © Diabetic gastroparesis
 © Intractable painful diabetic neuropathy
 © Extreme insulin sensitivity
 © Extreme insulin resistance
 © Severe injection site problems
 © True insulin allergy
 © Professional sports
YES
YES
NO
NO
YES
YES
YES TO ALL 
*NO TO ANY 
NO 
NO
* May not apply for some niche indications
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Who should be present at CSII initiation 
Individual teams should have skills and knowledge 
to undertake CSII initiation independently. Initiation 
is usually led by a specialist nurse or dietitian within 
the CSII team. The 2012 national insulin pump audit 
identified that CSII teams often relied on technology 
companies for CSII initiation and ongoing support. As 
teams become more confident with CSII, this reliance 
should reduce over time. Technology personnel 
should be experienced in both insulin pump initiation 
and optimisation.  It is important that the team are 
comfortable and skilled in the products they are using 
and while this may on occasion lead to reduced choice 
of pumps available within a service, safety of the insulin 
pump user must be paramount. An insulin pump service 
should only offer a range of pumps which they feel their 
team are able to safely support. 
Users may wish to have family or friends present at 
CSII initiation. This should be facilitated if possible to 
provide the individual with additional support.
Reviews after CSII initiation
Ideally the 1st year of pump initiation should include: 
• Week 1 pump therapy – daily telephone or email 
contact with specialist team member
• Week 2 pump therapy – twice weekly telephone and/
or email contact with specialist team member
• Week 4-5 pump therapy – face to face appointment 
with specialist team member for review and 
education. Pump downloads used to assess 
pump use, glucose levels, basal and bolus insulin 
requirements, alarm history and pump settings. 
• Thereafter pump users are encouraged to have 
telephone or email contact with the diabetes 
specialist team as required by individual for clinical 
support.
• Appointments in consultant led pump clinic MDT as 
follows in the 1st year of pump therapy initiation:
 - 3 months after initiation of pump therapy   
 - 6 months after initiation of pump therapy
 - 12 months after initiation of pump therapy
Factors for success on CSII  
To achieve the best possible outcome on CSII, the expert 
group identified the following factors which should be 
discussed with the person with diabetes to have realistic 
expectations of the actions required to achieve their 
therapeutic goals:
• Regular glucose monitoring (≥4 /day) 
• Use of the bolus calculator to calculate insulin doses 
• Bolus doses for all carbohydrates intake
• Regular set changes every 2-3 days, ideally early in 
the day
• Use of advanced features: temporary basal rates and 
dual wave boluses 
• Regular clinic attendance 
• Regular downloads and review of data 
(Scheiner et al. 2009, Wilkinson et al. 2010, Cukierman-
Yaffe et al. 2011) 
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Initial insulin setting at CSII initiation
Below is a summary flowchart to assist with dose calculation for CSII initiation, adapted from AACE (Consensus 
statement of AACE task force, 2014).
Calculations for Insulin Pump Settings
Pump TDD calculation
Method 1 Pre-pump TDD
Pre-pump TDD × 0.75
Method 2 Patient weight
Weight: kg × 0.5
Clinical considerations on pump TDD:
• Average values from methods 1 and 2
• Problematic hypoglycaemia: consider lower TDD
• Hyperglycemic, elevated HbA1c, or pregnant, consider higher TDD
Pump dose adjustment
Basal Rate 
(Pump TDD × 0.5)/24 h
Carbohydrate Ratio (I:C) ratio 
400/TDD
Insulin Sensitivity Factor (ISF)
130/TDD
• Start with one basal rate, adjust 
according to glucose values over 
basal rate testing
• Add additional basal according to 
need (e.g. Dawn phenomenon)
• e.g. TDD 35 units = 400/35 = 11.4, 
I:C ratio 1 unit: 11g 
• Most adults require 1 unit: 8-15g
• Acceptable post prandial rise is 
~3mmol/l
• Adjust based on low-fat meals with 
known quantity of carbohydrate 
• Correction insulin dose 
should bring glucose back to 
target range in 4-5 hours
 
Basal insulin
The basal rate is the amount of insulin infused per 
hour via CSII. The basal rate can be set hour by hour, 
facilitating flexible basal insulin delivery. The aim of 
the basal rate is to keep the glucose profile steady in the 
fasting state, with the aim of mimicking physiological 
requirements. It is important to recognise that basal 
requirements can vary significantly within the same 
person day-on-day, based on activity levels, illness and 
stress, and potentially changes in absorption from the 
insulin cannula (Ruan et al, 2016). 
The basal insulin on the pump should be roughly 30-
50% of the total daily dose, dependent on carbohydrate 
intake. Those with a high carbohydrate diet typically 
have a lower proportion of the total daily dose as basal 
insulin; those with a low carbohydrate diet have a greater 
proportion of their total daily dose as basal insulin.  
The basal insulin can be adjusted to meet individual 
insulin requirements throughout the day. 
Anticipated basal % of the total daily insulin dose:
• Basal 40-50% when:
 -  carbohydrate intake 100 - 200g/day
• Basal < 30% when:
 - high carbohydrate intake (> 200 g/day)
 - > 10 micro-boluses/day
• Basal > 50% when:
 - low carbohydrate intake
 - inadequate bolus insulin
 - using predictive suspend in some cases
 - insulin resistant (TDD > 0.7u/kg) 
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Basal rate patterns
A range of basal profiles have been advocated for 
insulin pump initiation:
• Flat basal profile (50% of TDD over 24 hours)
• Modified basal profile (4-6 basal profiles) (Figure 2 
and Table 2) 
• Circadian Profile (Renner Scale, Wizemann et al. 2001)
Ultimately any initial basal profile is a starting point 
which will be adjusted over time in response to review of 
the glycaemic profile. Some experts have been advocating 
‘circadian rhythm’ basal rate profiles which involve 
initiating users on a variable basal rate instead of a flat 
profile. However, the majority of the data underpinning 
circadian rhythm basal rates is from paediatric practice 
(Bachran et al. 2012) and it is not clear whether starting 
with a ‘circadian rhythm’ is superior to starting with a 
flat basal rate. Indeed, there is some evidence to suggest 
that high variability in the basal rate is associated with 
hypoglycaemia and ketoacidosis (Laimer et al. 2017).  
The best practice working group preferred a flat basal 
or modified basal rate over the circadian profile as the 
initial basal rate profile of choice. Regardless of the initial 
approach, the user must test and retest their basal rates 
to optimise control.  
Overall, many users tend to require an increase in 
the basal rate early in the morning, to counteract the 
'dawn-phenomenon', and lower rates between mid-
morning and mid-afternoon. Some users also require 
an increase in basal insulin in the evening, the 'dusk-
phenomenon', which may be related to a reduction 
in physical activity later in the day. If fixed periods 
of activity occur at the same time every day, such as 
walking or cycling to and from work, these can be 
accommodated for in the basal rate with reductions 
~60-90 minutes prior to the activity. A variety of basal 
rate patterns can be stored for different patterns (e.g. 
shift work, menstrual cycle etc.). Blood insulin levels 
settle into a steady state approximately 2-3 hours after 
a basal rate change, so it is desirable to change the 
basal rate in blocks of hours. Most users will require 
multiple basal rates, usually several though the day 
(Chico et al. 2014). There is evidence that those with 3-6 
basal rates have better outcomes. 
 
00:00 04:00
Late 
night
Early 
morning
↑20%† 
or more
 ↓20%*
 ↓ 10%
Morning EveningLate morning / 
afternoon
07:00 10:00 10:00 00:00
↑ 10%
Estimated hourly basal race
Rened basal
†Higher needed if 
marked dawn 
phenomenon. Lower if 
risk of night time 
hypoglycaemia 
*Lower if risk of night 
time hypoglycaemia
Figure 2. Modified Basal Rate Profile  
(Adapted from Hussain & Oliver: Insulin Pumps and Continuous Glucose Monitoring Made Easy, 1e, 2016, Elsevier Ltd) 
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Basal rate optimisation 
Basal insulin requirements can vary from day to day 
in Type 1 diabetes. However, it can be useful to ensure 
that CSII basal rates are close to the individual’s 
physiological requirements. To achieve this, basal 
rate assessment should be performed on a ‘normal’ 
day for the individual when there are no preceding 
external or internal factors which will change usual 
insulin requirements, such as stress, illness, exercise, 
hypoglycaemia, alcohol intake, menstruation or sleep 
deprivation.  It can be challenging to perform basal rate 
testing, and some may find this easier using CGM or 
flash glucose monitoring to gain more detailed insight 
into glucose patterns.  
There are a few strategies that can be used to optimise 
and adjust basal rates:
1. Formal basal rate testing. This is particularly 
useful for overnight/dawn phenomenon or 
troubleshooting or to help user understanding and 
engagement. See Appendix 1 for basal rate testing 
protocol. 
2. Opportunistic basal rate testing. This is easier 
to conduct using continuous or flash glucose 
monitoring to capture and assess glucose values 
in the fasting state >4 hours since last meal/bolus 
during day to day living. 
3. Download review. If the user is unable/unwilling to 
perform basal rate testing then the download can be 
interrogated to assess the appropriateness of basal 
insulin; although more challenging, this is probably 
the most common approach in clinical practice.
If the basal insulin is appropriate for that individual, 
then the glucose should not increase or decrease by 
more than 1.5 mmol/l in the fasting state. If it does, 
then the basal insulin should be increased or decreased 
as necessary 2 hours before the fluctuation in glucose 
values is identified. Once changes have been made, basal 
rate testing can be repeated to ensure the new basal 
insulin pattern is appropriate.
Temporary basal rates
Temporary basal rates allow users the option of changing 
the basal insulin delivery for a fixed period of time. It 
should be noted that following a change in basal insulin it 
can take anything from 2-6 hours for the insulin to reach 
steady state, therefore temporary basal rates are generally 
recommended if a longer term (hours) change in insulin 
delivery is required (McAulay et al 2017), although can 
be useful for exercise provided the change is made early 
enough. The change in basal insulin delivery should be 
made 1-2 hours before the desired change in blood glucose. 
Indications for temporary basal rate increase: 
• Illness
• Stress
• Pre-menstruation
• Reduced physical activity
Indications for temporary basal rate decrease:
• Increased physical activity
• Following alcohol 
Table 2. King’s Modified Basal Circadian Profile
Time of day Basel rate
Midnight to 3 hours before waking 80-100% of calculated units/hours
3 hours before waking to waking up 100%-120% of calculated units/hours
Waking up to lunch 80-100% of calculated units/hours
Lunch to evening meal 80-100% of calculated units/hours
Evening meal to bedtime 100%-120% of calculated units/hours
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Bolus insulin
Insulin timing
Rapid-acting insulin (Novorapid, Humalog, Apidra) 
bolus doses for meals should be administered 15-20 
minutes before eating as this is associated with a lower 
postprandial glucose excursion (Cobry et al 2010). The 
faster acting insulin analogue, Fiasp, is licensed for 
administration immediately pre or up to 20 minutes 
post meal (Slattery et al 2018).
Insulin:carbohydrate ratio (ICR)
A number of centres have traditionally used the 
500/100 rules to guide insulin dosing on pump therapy 
(Davidson et al, 2003). Following the publication of more 
recent data from King et al (King et al. 2016), there is a 
suggestion that more aggressive bolus doses and less 
aggressive corrections may be beneficial. The below 
recommendations are the consensus of a group of UK 
clinicians working with people with diabetes who use 
CSII. It should be noted that calculated ICR and insulin 
sensitivity factor (ISF) are a starting point which may 
require adjustment following review of downloaded 
insulin pump data.
Accurate carbohydrate estimation is a limiting factor 
in achieving excellent diabetes control. Although 
CSII does not remove the potential for human 
error in this calculation, it does allow for accurate 
insulin to carbohydrate ratios, to the nearest gram of 
carbohydrate. However, despite this, many CSII users 
continue to input rounded carbohydrate amounts (e.g. 
10g vs 12g) and also use inaccurate and rounded ratios 
such as 1unit:10g CHO or 1unit:15g CHO (Walsh et al. 
2010). This practice reflects previous approaches utilised 
for manual calculations whilst on MDI therapy and, 
possibly, the preference of the health care provider. 
However, such an approach prevents the delivery of 
accurate insulin therapy which has implications for 
short and long term glycaemic control. For instance, 
changing the ratio from 1unit:10g to 1unit:9g lowers 
the post-prandial glucose by 1.8-2.9 mmol/l at each 
meal for an average individual consuming 60-100g of 
carbohydrate (Walsh et al, 2010).
The consensus of the group was to routinely start 
with 400/TDD (Figure 3). Some people may need more 
aggressive boluses, especially at breakfast with ratios of 
of up to 300/TDD.
To calculate the ICR, 400 is divided by the total daily 
insulin dose to provide an indication of how many 
grams of carbohydrate 1 unit of insulin will cover (see 
example). Some users may require different ICR and ISF 
for different times in the day dependent on factors such 
as individual diurnal variation and activity levels.
The calculated ICR and ISF are useful when 
troubleshooting potential causes of hypoglycaemia and 
hyperglycaemia. If hyperglycaemia is persistent once 
other factors have been excluded, then the TDD can be 
increased by 5-10% and the ratios re-calculated.
Insulin sensitivity factor (ISF)
The ISF, or correction factor, is a guide to the reduction 
in blood glucose, in mmol/l, which can be expected when 
giving 1 unit of insulin. It is important to get this ratio 
correct as users will rely on this to reduce unexpectedly 
high blood glucose values. Those previously on MDI 
will have been used to crude corrections of 1 unit:2-3 
mmol/l which would often have prevented them from 
correcting glucose values <10 mmol/l, due to a fear of 
hypoglycaemia. However, CSII allows for the delivery of 
correction doses to the nearest 0.1 unit of insulin which, 
combined with the reduced variation in the absorption 
of insulin allows for accurate corrections of near normal 
glucose values without the fear of hypoglycaemia.
There are a number of 'rules' in the literature, none of 
which have been compared head to head. The most 
widely used is the 100 rule [ISF = 100/TDD], although 
many now advocate a more gentle correction of 120-130/
TDD. The consensus of the group was to routinely start 
with the 130 rule [ISF = 130/TDD] (Figure 3). To achieve 
the optimal ISF 130 is divided by the TDD to provide an 
estimate of how much 1 unit of insulin will reduce the 
blood glucose by in mmol/l. 
It should be remembered that the ICR and ISF rules 
are not absolute and should be used as rough starting 
points which should be adjusted based on subsequent 
glucose readings. Any adjustments to ICR and ISF need 
to be tested and revised accordingly. The ISF should 
bring the glucose into target after 4-5 hours. Ideally 
the ISF should be tested when the last bolus was more 
than 5 hours ago, carbohydrate was consumed more 
than 3 hours ago and the user can wait 4-5 hours until 
they next eat. 
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Target ranges
Choosing an appropriate glucose target range when using 
CSII is of paramount importance. Some devices correct to 
the higher figures in the target range (e.g. Medtronic), others 
correct to the mid range (e.g. Roche), whilst others have a 
single target glucose value but define a threshold glucose 
above which a correction bolus will be calculated (e.g. 
Omnipod). To overcome this, the expert group would advise 
an individualized narrow target range of +/- 1mmol/l 
(e.g. 4.5-5.5mmol/l target range, or target glucose of 5.0 
mmol/l) for all pumps to minimise the risk of user error. 
Targets should be individualised to a level the user 
is comfortable with. For instance, those with a high 
HbA1c may need an initially higher target range 
as they may experience hypoglycaemia symptoms 
at normoglycaemic glucose values, until they get 
accustomed to lower glucose values than they have 
been used to. 
Figure 3 Insulin pump settings
Settings
Total Daily Dose (TDD) If problematic hypoglycaemia consider a 10% reduction
Insulin:Carbohydrate ratio 300-400/TDD
Insulin Sensitivity Factor (ISF) 130/TDD
Insulin active time 4 hours*
Blood glucose target 5 mmol/l**
Table 3: Predicted ICR and ISF based on insulin pump total daily dose (TDD)
TDD I:C Ratio 
1 unit of insulin for X g of carbs
ISF
1 unit reduces glucose by...
400 rule 130 rule
10 40 13
20 20 6.5
30 13 4.3
40 10 3.3
50 8 2.6
60 7 2.2
70 6 1.9
Example: calculating the desired insulin
John has a total daily insulin dose of 36 units.
Using the ‘400 rule’ to calculate ICR 
Insulin:CHO ratio = 400/TDD = 400/36 = 11.1 = 1 unit:11g CHO 
Using the ‘130 rule’ to calculate ISF
ISF= 130/TDD = 130/36 = 3.6 = 1 unit reduces glucose by 3.6 mmol/l
John is going to eat a sandwich which contains 46g of carbohydrate. His target glucose is 5 mmol/l. His glucose 
before lunch is 11.8 mmol/l. How much insulin should he administer?
ICF 1unit:11g, so for sandwich needs 46g / 11 = 4.2 units
ISF 1unit:3.6 mmol/l so to correct from 11.8 to 5 mmol/l: 11.8 - 5mmol/l = 6.8mmol/l /3.6 = 1.9 unit
Total bolus insulin dose required = 4.2 + 1.9 = 6.1 units
* For TDD <30 units per day consider reduced 
insulin active time
* Consider longer active insulin time in renal 
failure (GFR<45), or bolus size>10 or TDD>60
** Targets need to be individually tailored. For 
HbA1c >86 mmol/mol (10%) consider a BG 
target 9-10 with the plan to reduce target every 
month by 1 mmol/l to create a gradual fall in 
HbA1c. This is particularly important that those 
with retinopathy. Different pump bolus advisors 
calculate correction targets differently, the 
reason to suggesting single value or a narrow 
range (4.5-5.5mmol/l) is that it overcomes 
issues with this. 
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Such calculations are complex. It is important that 
users are encouraged to use their bolus calculator to 
facilitate accurate insulin delivery. An accurate insulin 
bolus should bring the glucose close to target 4-5 hours 
after administration. If this is not the case, the ratios 
will need to be reassessed and altered as necessary.
 
While these rules may not work perfectly for every 
person with diabetes, they are good starting point and 
encourage thinking beyond simple rounded ratios 
e.g. 1unit:10g. Modern pumps have integrated bolus 
calculators, allowing the user to programme their ratios, 
saving them from performing complex arithmetic at 
mealtimes. In consultation with CSII users it is worth 
ensuring that they are using the bolus calculator and 
that the settings are appropriate and up to date. Pump 
users often report mistrust of the bolus calculator 
settings as a reason for not using it, so they should be 
made aware that this is an indication for adjusting the 
settings, in conjunction with a member of the diabetes 
team if needed, not rejecting the calculator function. An 
adequate insulin:CHO ratio should control the post-
prandial glucose. A rise of 2-4mmol/l at 2 hours would 
be considered reasonable except in pregnancy when a 
lower increment would be desirable.
Advanced bolus features
Insulin pumps have the ability to deliver a bolus of 
insulin in a variety of options (see below):
Time
Three Types of Bolus Insulin
In
su
lin
1 2 3
Normal 
Bolus
Square-Wave 
Bolus
Dual-Wave 
Bolus
• A square wave or extended bolus delivers insulin 
over a fixed extended period
• A dual or combination bolus delivers a percentage 
of the insulin as a normal bolus and the remainder 
over a fixed period.
The aim of these advanced bolus options is to better 
match insulin delivery to dietary intake and minimise 
the post prandial glucose excursion. These advanced 
features can be added to therapy once the user is 
established on their CSII therapy. Audit data and other 
surveys suggest that few people use these features 
routinely (Groat et al, 2017).
Meals high in fat and/or protein can be associated with 
prolonged raised glucose values, particularly overnight, 
leading to morning hyperglycaemia. Common examples 
of these meals might include Indian or Asian cuisine, 
pizza, cheese with pasta or fish and chips. However 
considerable inter-individual differences exist in the 
impact of fat, protein and GI index of carbohydrates 
on postprandial glucose levels, making it very difficult 
to come up with uniform algorithms for dose advice. 
Based on published literature, we recommend that for 
high protein and high fat meals (>40 g fat, >25 g protein), 
individuals with Type 1 diabetes should initially consider 
increasing the insulin dose calculated from their ICR 
by 25%–30% and using a dual wave (combination) bolus 
with 50%–70% given initially and the remainder over 
2–6 hours depending on the individual’s experience (Bell 
et al. 2015, Bell et al. 2016, Lopez et al. 2017). If the review 
of glucose profiles shows late (>3 h) hyperglycemia 
or early hypoglycaemia, then for subsequent meals 
of similar composition the insulin delivered in the 
immediate and extended period should be adjusted. 
Guide to download interpretation
All CSII centres should routinely download insulin 
pumps and interrogate the data obtained. We 
recommend review of the download as an essential part 
of the consultation with the person with diabetes. Users 
should also be encouraged to review their data prior 
to clinic attendance. Pumps can be downloaded using 
proprietary software such as Medtronic Carelink, Roche 
360, or general software such as Diasend/Glooko.
Most clinicians will develop their own preference for the 
order in which they review these aspects, but ultimately 
all aspects should be covered. The following should be 
considered when reviewing an insulin pump download:
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Table 4. A guide to insulin pump download interpretation
Glucose Insulin Pump settings
• What is the frequency of glucose 
monitoring?
 - Be aware that in those 
achieving HbA1c < 58mmol/
mol (7.5%)  the average BG 
tests per day is ≥ 5
• What is the mean glucose and 
therefore estimated HbA1c?
• What is the glycaemic variability? 
 - Standard deviation (SD) ≥ 3.5 
mmol/l or CV  
(SD/mean) ≥ 36% suggests 
high variability (Danne et al. 
2017)
• What percentage of time is spent in 
hypoglycaemia?
 - ≥ 10% in someone monitoring  
≥ 4/day is a concern, so 
identify the cause.
• What percentage of the total daily 
dose is basal? 
 - ~40-60% expected - but 
take number of boluses and 
carbohydrate intake into 
account
• Is the basal insulin adequate?
 - Is the glucose stable overnight 
and fasting at times when 
there are no other confounding 
factors?
• What is the frequency of boluses? 
 - Is all carbohydrate covered 
with a bolus?
 - Optimal glucose control often 
requires ≥  
5 bolus /day
• What is the total daily dose? 
• Do the I:C ratio and ISF fit with 
expectations taking into account 
the 400 and 130 rules?
• If more insulin resistant at certain 
points of the day, are I:C and ISF in 
keeping with this?
• Are set changes occurring at least 
every 3 days?
• Is the bolus calculator used for the 
majority of boluses?
 - Is bolus calculator advice being 
over-ridden?
• What is the target range? 
 - Remember Medtronic pumps 
correct to the upper level so 
consider using 4.5-5.5mmol/l 
for most to overcome this - 
but do individualise targets 
following discussion with users.
• If settings are way off those 
expected, with ineffective basal 
rates and bolus ratios, and sub-
optimal control, consider resetting 
insulin pump settings based on 
weight calculations. Note that 
this will require close contact 
thereafter for further optimisation.
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Management of unexplained hyperglycaemia
Set failure can occur and if not detected can potentially 
result in the development of ketosis/ketoacidosis within 
a matter of hours. All people with diabetes who use 
insulin pump therapy should be aware of the potential 
for set failure and how to manage this.
Rules for the management of unexplained hyperglycaemia:
• If glucose >13 mmol/l, take a correction bolus by  
the pump
• Check BG in 2 hours - if no change or glucose is 
higher, take a correction injection with a syringe or 
pen, check for ketones
• Change infusion set and reservoir
• Check glucose and blood ketones in 2 hours and take 
a correction bolus via the pump if required, check 
for ketones if glucose still high
• Follow sick day rules if ketones are positive
• Do not go to sleep: 
 - with unexplained hyperglycaemia which has 
not resolved 
 - or, within 2 hours of a new set change
Insulin pump users should be encouraged to explore the 
reasons why the high glucose has occurred (see table 5) 
(Ponder et al. 2008).
All CSII users should be advised to perform set changes 
early in the day, not in the evening.
Insulin pump therapy users must carry, or have 
access to, an alternative means of insulin delivery 
(pens or syringe). They should also have access to long 
acting insulin and know the dose to take in the event 
of pump failure. 
Back up insulin pens
Pump users should have some long acting insulin 
available to them which they can use in the event of 
CSII failure. This is particularly important if they are 
travelling away from home. Users should carry a note 
of their ICR, ISF and basal insulin requirements. In the 
event of CSII failure, the emergency basal insulin would 
be the same as the total daily basal insulin on the pump 
and the ICR/ICF would be the same as on the pump.
In the event that a user experiences pump failure but 
they do not have long acting insulin with them, they 
should check glucose and take an injection of rapid 
acting insulin every 3 hours. 
Some users may wish to plan a temporary return to 
multiple daily injections for holidays; they should be 
supported to do this. Some pump companies offer a 
holiday loan pump.
CSII AND SPECIFIC SCENARIOS
Table 5 Causes of unexplained hyperglycaemia
Possible causes of unexplained hyperglycaemia
Infusion Set Insulin Pump Insulin
• Is the tubing primed or filled with 
insulin?
• Is there air in the tubing? 
• Did you remember to fill the 
cannula with insulin after inserting 
new set?
• Is the tubing connected to the 
cartridge?
• Is the set connected to your body?
• Are there any leaks?
• Is the cannula dislodged or kinked?
• Has the infusion set been in longer 
than 2-3 days?
• Is there redness or discomfort at 
the site?
• Is there blood on/at the site?
• Did you forget your last bolus?
• Have you received any recent 
alarms? 
• Is your cartridge empty?
• Is the date and time correct?
• Are your basal rates programmed 
correctly?
• Is your insulin expired/inactive?
• Has your insulin been exposed to 
extreme temperatures?
• How long has the insulin been in 
the cartridge and tubing?
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Sick day rules
Insulin pump therapy users should be provided with sick day rules and access to in date blood ketone monitoring. They 
should be advised to check for ketones if they feel unwell. Figure 5 details sick day rules for pump therapy.
Feel unwell? 
Test blood glucose (BG) and ketones 
Sip sugar-free fluids (at least 100ml/hour)
If you continue to vomit, are unable to keep fluids down, or unable to control your 
blood glucose or ketones you must go to the hospital as an emergency.
You must never suspend/stop your pump
Test blood glucose and ketones every 2-4 hours
• Usual insulin:carbohydrate ratio if eating
• Use corrective boluses if BG is raised, 
even if you are not eating. 
• When unwell you may find you need 
larger bolus doses to reduce blood 
glucose – override the bolus adviser.
• If glucose levels are persistently 
above target, consider an increase 
of 10 – 20% in basal rate by using 
an increased temporary basal.
• You may only need your usual basal insulin 
if not eating and your BG is in target range
Test blood glucose and ketones every 2 hours
Calculate Total Daily Dose (TDD) 
from previous day
Ketones
+  -  ++ on urine test
1.5–3 mmol/l 
on blood test
Give 10% of TDD as 
bolus insulin every 
2 hours plus usual 
insulin:carbohydrate 
ratio if eating and 
↑basal by 30%
Override the 
bolus adviser
Ketones
+++  -  ++++
Over 3 mmol/l 
on blood test
Give 20% of TDD as 
bolus insulin every 
2 hours, plus usual 
insulin:carbohydrate 
ratio if eating 
and↑basal by 
50% or more
Override the 
bolus adviser
NO KETONES 
(negative or trace on urine test; less 
than 1.5mmol/l on blood  test)
MINOR ILLNESS
KETONES PRESENT
(more than a trace on urine test ; more 
than 1.5mmol/l on blood test)
Blood glucose raised (usually above 13 mmol/l)
SEVERE ILLNESS
Figure 5: Pump sick day rules (copyright DAFNE UK)
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Problematic hypoglycaemia
Disabling hypoglycaemia is defined as the repeated and 
unpredictable occurrence of hypoglycaemia that results 
in persistent anxiety about recurrence and is associated 
with a significant adverse effect on quality of life.
 
All people with Type 1 diabetes should have annual 
screening for impaired awareness of hypoglycemia with 
validated tools such as
• Gold score
• Clarke Score
These tools show consistency between them 
and identify those with increased risk of severe 
hypoglycaemia events (SHE).  On a meter download, if 
there are >10% of readings < 4 mmol/l, or >3 readings 
<3 mmol/l per week, this may also be considered as 
increased frequency of hypoglycaemia that may 
identify those at increased risk of SHE. 
The International Hypoglycaemia Study Group (IHSG, 
2017) have recently recommended that blood or sensor 
glucose readings <3.0 mmol/l should be considered 
as serious, clinically important hypoglycaemia. 
Problematic hypoglycemia should be considered as 
frequent readings below this level (> 2/week). 
 
CSII should result in improvements in hypoglycaemia. 
If it does not, then next steps need to be considered 
which include sensor augmented pump therapy (SAP) 
and islet cell transplantation (see figure 5). The MDT 
should consider whether the individual meets the NICE 
guidance (NG17, DG21) for sensor augmented pump 
therapy in the first instance.
Sensor Augmented Pump Therapy NICE DG21
NICE recommendations: 
• The MiniMed Paradigm Veo system is recommended 
as an option for monitoring blood glucose levels in 
people with Type 1 diabetes who:
 - have repeated and unpredictable episodes 
of disabling hypoglycaemia despite optimal 
management with continuous subcutaneous 
insulin infusion or
 - feel ongoing anxiety about these episodes 
happening again.
The Medtronic Paradigm Veo system has been 
superseded by the Medtronic 640G system with 
Predictive Low Glucose Management and now has 
evidence demonstrating reduction in hypoglycaemia 
frequency (Choudhary et al. 2016).
If the team has little experience in managing 
problematic hypoglycaemia and the use of sensor 
augmented pump therapy, then consider referral onto 
a specialist hypoglycaemia 'hub' centre. Similarly, 
if the user has a trial of SAP with no improvement, 
they should be referred to a dedicated hypoglycaemia 
service for review and consideration for islet cell 
transplantation and/or pancreas transplant (figure 6).
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KEY:
 e Level I to II Evidence
 e Level III to IV Evidence
• MDI – Multiple 
dose injection
• SMBG – self monitoring 
blood glucose
• CSII – Continuous 
subcutaneous 
insulin infusion
• SAP – Sensor 
augmented pump
• LGS – Low glucose 
suspend
• RT-CGM – Real 
time CGM
• SH - Severe 
Hypoglycaemia
Reassess 
Every 3 to 6 
Months
If SH or Gold / Clarke score ≥ 4 progress to next level 
Consider First Line
Evaluate Underlying Causes and Status Against Treatment Targets
Consider Second Line
Consider Third Line
Consider Fourth Line
Structured Education
CSII with SMBG
SAP with LGS
SAP without LGS
Islet Transplant
Hypoglycaemia-Specific
Education
MDI with RT-CGM
Very Frequent Contact
[Weekly for 3-4 Months]
Pancreas Transplant
or
or
and/or
or
Figure 6 Approach to the person with problematic hypoglycaemia (adapted from Choudhary et al 2015)
Insulin pump renewal 
Prior to CSII renewals there should be documented 
evidence of ongoing clinical benefit as demonstrated 
over the previous 4 years.
Most centres routinely replace insulin pumps when the 
warranty expires. Advantages include access to holiday 
‘loan’ pumps and reassurance that the company will 
quickly replace the pump in the event of a fault.
Some centres may choose not to routinely replace 
insulin pumps when the warranty expires. While this 
reduces costs, there is a potential risk of pump failure 
beyond the warranty period and as such there is a need, 
in this situation, to ensure the local hospital can supply 
an emergency pump in the event of pump failure. The 
decision on policy for ‘out of warranty pumps’ should be 
decided at a local Trust level and clearly communicated 
to people with diabetes. 
The point of pump renewal is an important time to 
review and assess the benefit of pump therapy over the 
4 years to ensure that the aims of pump therapy have 
been achieved. 
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Discontinuation of insulin pump therapy 
In some circumstances the MDT may feel it is 
appropriate to consider discontinuation of insulin pump 
therapy: either when insulin pump therapy is not safe 
or there is an absence of clinical benefit. In some cases, 
such as the absence of adequate glucose testing, this can 
be a temporary discontinuation until the user is safe to 
use insulin pump therapy again.  
Consider CSII discontinuation in the following 
circumstances:
1. User choice 
User would prefer MDI
2. Safety concerns
a. Admission with ketosis/diabetic ketoacidosis 
related to unsafe insulin pump use
b. Inadequate glucose monitoring (<4 / day on 
download)
i. If monitoring <2 per day, consider 
temporary immediate withdrawal on the 
basis of safety concerns 
ii. If monitoring 2-4 times per day, consider 
withdrawal if unable to increase to >4 times 
per day
c. Unable to self-manage CSII safely (user or carer, 
e.g. cognitive impairment)
d. Non-attendance at clinic for review
3. Absence of clinical benefit 
Failure to meet the objectives of CSII described 
at pump start eg failure to improve HbA1c and /
or reduce hypoglycaemia frequency in absence of 
extenuating circumstances 
If pump therapy is withdrawn due to safety concerns, this 
should be done in a supportive way, with a plan to provide 
educational and psychological support to be able to move 
towards being able to restore pump therapy again if 
appropriate. This should be done with MDT input. 
Transition
The principles of best practice for transition of care 
from paediatric care to adult services (NG18; NICE 
QS125) should apply to adolescents with Type 1 
diabetes on insulin pumps. There are typically a higher 
proportion of the paediatric population using insulin 
pump therapy than in adult services (28% paediatric 
vs 15% adults with T1DM using pumps in the 2016 
national audit) because the NICE criteria allow access 
to pump therapy for a greater breadth of indications 
for those with T1DM aged 11 and under. These pump 
users will be transitioning into adult services in 
the years to come. It is imperative that the adult 
team looking after young adults have both the skills 
and capacity to continue to support young people 
using insulin pump therapy. Paediatric and adult 
services should liaise to ensure that the insulin pump 
equipment used is familiar to both teams.
Paediatric best practice tariff allows a minimum 
follow-up of 3 monthly consultant led MDT clinic 
appointments plus telephone contacts, significantly 
more than that typically available in adult services. 
Young adult services need to be aware of this and 
attempt to maintain contact and reinforce contact 
points and safe pump use. There is the potential for 
adolescent pump users to miss out on the benefits 
of transition diabetes services because they are 
transferred from paediatric to adult pump service. 
Ideally these adolescent pump users should be seen in 
both a transition clinic and pump clinic, but if this is 
not an option follow up in a transition clinic with pump 
specialist input should be the default arrangement.
NICE guidance states that children initiated on insulin 
pump therapy should expect a trial of MDI between 
the ages of 12 and 18. In practice this is not a policy 
supported by UK practice. However, it is important 
to recognise that often pump education has been 
directed at parents rather than children, and so as the 
adolescent pump user becomes more autonomous 
in managing their diabetes they may not have the 
education, and hence skills to optimise pump therapy. 
Transition services should make sure that adolescent 
pump users are offered appropriate education to 
develop the necessary skills for optimal usage of CSII 
and should allow adolescent pump users a pump 
holiday where they can try MDI without perceiving 
this as a failure on their part.
It is good practice for paediatric teams, who already 
have a relationship with the young person with 
diabetes and family, to discuss about possible future 
pump holidays/ trials of MDI prior to transition rather 
than leaving these potentially difficult conversations 
to the new adult team.
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Exercise
The flexibility in insulin delivery which is available 
through insulin pump therapy can help to reduce 
the dysglycaemia associated with exercise in Type 1 
Diabetes (Riddell MC et al. 2017). Responses to exercise 
are individual and so all adjustments recommended 
here should be used as a starting point and are likely to 
need adjustment based on glucose trends. 
Aerobic exercise
The most common type of exercise people will undertake 
is aerobic exercise. This is exercise (often running, cycling, 
swimming) at an intensity which can be maintained for 
around 30 minutes or longer. In Type 1 diabetes, this is 
associated with the possibility of hypoglycaemia during, 
soon after, or some hours post exercise completion. 
Higher circulating insulin at the start of activity is 
associated with a higher risk of hypoglycaemia, and so 
where possible basal insulin should be reduced 60-90 
minutes before activity starts. The optimal reduction 
in basal insulin is likely between 50 and 100% (total 
suspension), with a reduction of 80% a useful starting 
point. Basal insulin can be returned to the usual rate at 
the end of exercise, although extending the temporary 
reduction for longer may be necessary depending on 
glucose trends. Where exercise is within 90-120 minutes 
after food, a 50% reduction in bolus insulin is likely to be 
more effective in reducing the risk of hypoglycaemia.
Anaerobic exercise
Anaerobic (high intensity) exercise is associated with a 
counter-regulatory response which can result in a rise 
in blood glucose. Where this is observed, a temporary 
increase in basal insulin may be helpful, ideally starting 
30-60 minutes prior to the activity. Initially an increase 
of 20% may be helpful, although this should be adjusted 
based on glucose trends. An alternative is to correct 
any hyperglycaemia which does arise using 50% of the 
correction dose calculated using the usual ISF.
Combined exercise
Where anaerobic exercise is mixed with aerobic exercise 
(such as in many exercise classes) the overall result is 
usually a fall in glucose which is attenuated compared 
to the fall in glucose seen with aerobic exercise alone. In 
this instance a reduction in basal insulin should be used 
as above, with the starting point a reduction in basal 
insulin of 50%.
Nocturnal Hypoglycaemia
Nocturnal hypoglycaemia is commonly associated with 
exercise in Type 1 diabetes, particularly when the exercise 
has been of unusual intensity or duration, or when it has 
happened later in the day. The risk of this can be reduced 
by making a 20% reduction in basal insulin to last for 4-6 
hours from the time of going to bed. 
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Considerations when exercising using an insulin pump:
• Not all pumps are waterproof – some may need to 
be removed for swimming or other watersports
• It may not be possible to wear an insulin pump for 
some contact sports
• Activity can increase the risk of cannula 
displacement, so careful monitoring of glucose (and 
ketones) is advised
• Any heated room, or exercising in warm weather may 
accelerate insulin absorption and/or magnify the 
effect of the infusion rate for any given pump setting
Exercising when pump is removed or basal insulin suspended
A time limit of 2 hours is recommended for the 
suspension of basal insulin infusion and/or the 
removal of the insulin pump. Should the activity last 
longer than this one option is to re-connect the pump 
hourly and administer a bolus of 20-50% of the basal 
insulin which would have been given during that hour. 
Where this is not practical (e.g. for some watersports), 
and especially where the removal is likely to last for a 
longer period, an alternative is to remove the insulin 
pump for 6-12 hours and administer basal insulin 
using a single dose of NPH insulin or Levemir. The 
required dose will depend on the nature of the activity 
and individual glucose responses but a starting point 
would be 50% of the missed basal insulin.
Signposting
Longstanding pump users can provide a useful 
'buddying' service to those starting insulin pump 
therapy. Several centres have pioneered this.
Those keen to find out more about insulin pump 
therapy can be pointed towards the following resources 
and support networks:
• INPUT Patient Advocacy www.inputdiabetes.org.uk 
• Twitter #GBDOC   
• JDRF www.jdrf.org.uk
• Diabetes UK www.diabetes.org.uk
• Type 1 resources www.t1resources.co.uk
• Insulin Pumps Wales www.insulinpumpswales.org.uk 
Conclusion
In summary, insulin pump therapy is an effective self-
management tool for people living with Type 1 diabetes. 
Insulin pump use is associated with improvements in 
glucose control, hypoglycaemia and quality of life. The 
uptake of insulin pumps across the UK has demonstrated 
unacceptable variation which must be addressed. It is 
the hope of the authors of this guide that by providing 
consensus on UK Best Practice that health care 
professionals will feel more confident to deliver and 
promote CSII therapy for those living with diabetes.
027CLINICAL GUIDELINE 
BEST PRACTICE GUIDE
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) 
Aronson R, Cohen O, Conget I, et al. OpT2mise: A randomized controlled 
trial to compare insulin pump therapy with multiple daily injections in 
the treatment of type 2 diabetes. Diabetes Technol Ther 2014;16:414-420
American Association of Clinical Endocrinologists/American College 
of Endocrinology Insulin Pump Management Task Force consensus 
statement. Endocrine Practice 2014;20:462-489
Bachran R, Beyer P, Klinkert C et al. Basal rates and circadian profiles 
in continuous subcutaneous insulin infusion (CSII) differ for preschool 
children, prepubertal children, adolescents and young adults. Pediatric 
Diabetes 2012;13:1-5.
Batellino T, Conget I, Olsen B et al The use and efficacy of continuous 
glucose monitoring in type 1 diabetes treated with insulin pump 
therapy: a randomised controlled trial.  Diabetologia 2012;55:3155-62. 
Beato-Vibora P, Yeoh E, Rogers H et al. Sustained benefit of continuous 
subcutaneous insulin infusion on glycaemic control and hypoglycaemia 
in adults with Type 1 diabetes. Diabet Med 2015;32:1453-9.
Bell KJ, Smart CE, Steil GM et al. Impact of fat, protein, and glycemic 
index on postprandial glucose control in Type 1 Diabetes: implications 
for intensive diabetes management in the continuous glucose 
monitoring era. Diabetes Care 2015;38:1008–1015
Bell KJ, Toschi E, Steil GM, Wolpert HA. Optimized mealtime insulin 
dosing for fat and protein in Type 1 Diabetes: application of a model-
based approach to derive insulin doses for open-loop diabetes 
management Diabetes Care 2016;39:1631–1634. 
Bergenstal RM, Tamborlane WV, Ahmann A et al STAR 3 Study Group. 
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: 
results from the 6-month continuation phase. Diabetes Care 2011 
Nov;34(11):2403-5.
Bode BW, Steed RD, Davidson PC (1996) Reduction in severe 
hypoglycemia with long-term continuous subcutaneous insulin 
infusion in type I diabetes. Diabetes Care 19: 324–7
Boulton AJM, Drury J, Clarke B et al. Continuous Subcutaneous 
Insulin Infusion in the Management of Painful Diabetic Neuropathy. 
Diabetes Care 1982;5:386-90.
Bruttomesso D, Crazzolari D, Maran A, et al. In type 1 diabetic patients 
with good glycaemic control, blood glucose variability is lower during 
continuous subcutaneous insulin infusion than during multiple daily 
injections with insulin glargine. Diabet Med 2008;25:326-32.
Chico A, Tundidor D, de Leiva A. Changes in insulin requirements from 
the onset of continuous subcutaneous insulin infusion (CSII) until 
optimization of glycemic control J Diabetes Sci Technol 2014;8:371-77
Choudhary P, Ramadamy S, Green L et al. Real-time continuous glucose 
monitoring significantly reduces hypoglycemia in hypoglycemia-
unaware patients with type 1 diabetes. Diabetes Care 2013;36:1460-2
Choudhary P, Rickels MR, Senior PA, et al. Evidence-informed clinical 
practice recommendations for treatment of type 1 diabetes complicated 
by problematic hypoglycemia. Diabetes Care. 2015 Jun;38(6):1016-29
Choudhary P, Olsen BS, Conget I et al.Hypoglycemia Prevention and 
user acceptance of an insulin pump system with predictive low glucose 
management Diabetes Technol Ther 2016;18:288-91.
Cobry E, McFann K, Messer L et al. Timing of meal insulin boluses to 
achieve optimal postprandial glycemic control in patients with type 1 
diabetes. Diabetes Technol Ther 2010;12:173-7.
Cukierman-Yaffe T, Konvalina N, Cohen O. Key elements for successful 
intensive insulin pump therapy in individuals with type 1 diabetes. 
Diabetes Res Clin Pract 2011;92:69-73.
Danne T, Nimri R, Battelino T et al. International consensus on use of 
continuous glucose monitoring. Diabetes Care 2017;40:1631-40.
Davidson PC, Hebblewhite HR, Bode BW, et al. Statistically based CSII 
parameters: correction factor (CF) (1700 rule), carbohydrate-insulin ratio 
(CIR) (2.8 rule), and basal-to-total ratio. Diabetes Technol Ther 2003;5:237-42.
Groat D, Grando MA, Soni H et al. Self-Management behaviors in adults 
on insulin pump therapy. What are patients really doing? J Diabetes Sci 
Technol 2017;11:233-9.
Heinemann L, Alexander GF, Petrie JR et al Insulin pump risks and 
benefits: a clinical appraisal of pump safety standards, adverse event 
reporting and research needs. A Joint Statement of the European 
Association for the Study of Diabetes and the American Diabetes 
Association Diabetes Technology Working Group. Diabetologia 
2015;58:862-70.
Hoogma RP, Hammond PJ, Gomis R et al. Comparison of the effects 
of continuous subcutaneous insulin infusion (CSII) and NPH-based 
multiple daily insulin injections (MDI) on glycaemic control and 
quality of life: results of the 5-nations trial. Diabet Med 2006;23:141-147.
Hussain S & Oliver N: Insulin Pumps and Continuous Glucose 
Monitoring Made Easy, 1e, 2016, Elsevier Ltd
International Hypoglycaemia Study Group. Glucose concentrations 
of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: 
a joint position statement of the American Diabetes Association and 
the European Association for the Study of Diabetes. Diabetes Care 
2017;40:155-157.  
King AB, Kuroda A, Matsuhisa M, Hobbs T. A review of insulin-dosing 
formulas for continuous subcutaneous insulin infusion (CSII) for 
adults with Type 1 Diabetes. Curr Diab Rep 2016;16:83-90.
Laimer M, Melmer A, Mader JK et al. Variability of basal rate profiles 
in insulin pump therapy and association with complications in type 1 
diabetes mellitus. PLoS One 2016;11:e0150604.
Leelarathna L, Roberts SA, Hindle A et al. Comparison of different 
insulin pump makes under routine care conditions in adults with Type 
1 diabetes. Diabet Med 2017;34:1372-9.
Lopez PE, Smart CE, McElduff P et al. Optimizing the combination 
insulin bolus split for a high-fat, high-protein meal in children and 
adolescents using insulin pump therapy. Diabet Med 2017;34:1380-4. 
REFERENCES
028 CLINICAL GUIDELINE 
BEST PRACTICE GUIDE
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) 
Ly TT, Nicholas JA, Retterath A et al. Effect of sensor-augmented 
insulin pump therapy and automated insulin suspension vs standard 
insulin pump therapy on hypoglycemia in patients with type 1 
diabetes: a randomized clinical trial. JAMA 2013;310:1240-7.
McAuley SA, Ward GM, Horsburgh JC et al. Asymmetric changes in 
circulating insulin levels after an increase compared with a reduction 
in insulin pump basal rate in people with Type 1 diabetes. Diabet Med 
2017;34:1158-64.
National Institute for Health and Clinical Excellence Continuous 
subcutaneous insulin infusion for the treatment of diabetes mellitus. 
NICE, London, 2008. https://www.nice.org.uk/Guidance/TA151
NICE diagnostics guidance [DG21] Integrated sensor-augmented pump 
therapy systems for managing blood glucose levels in type 1 diabetes 
(the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM 
CGM system). February, 2016 https://www.nice.org.uk/guidance/dg21
NICE guideline [NG3] Diabetes in pregnancy: management from 
preconception to the postnatal period. Last updated: August 2015 
https://www.nice.org.uk/guidance/ng3
NICE guideline [NG17] Type 1 diabetes in adults: diagnosis and management. 
Last updated: July 2016 https://www.nice.org.uk/guidance/ng17
NICE guideline [NG18] Diabetes (type 1 and type 2) in children and 
young people: diagnosis and management. Last updated: November 
2016 https://www.nice.org.uk/guidance/ng18
NICE quality standard [QS125] Diabetes in children and young people. 
Published: July 2016  https://www.nice.org.uk/guidance/qs125
Pickup JC, Sutton AJ. Severe hypoglycaemia and glycemic control in 
Insulin Dependant Diabetes: meta-analysis of multiple daily insulin 
injections compared with continuous subcutaneous insulin infusion 
Diabet Med 2008;25:765–74.
Pickup JC, Yemane N, Brackenridge A, Pender S. Nonmetabolic 
complications of continuous subcutaneous insulin infusion: a patient 
survey. Diabetes Technol Ther 2014;16:145-9. 
Ponder SW, Skyler JS, Kruger DF et al..Unexplained hyperglycemia in 
continuous subcutaneous insulin infusion: evaluation and treatment. 
Diabetes Educ. 2008;34:327-33. 
Pratt E, Miles P, Kerr D. Localized insulin allergy treated with 
continuous subcutaneous insulin Diab Med 2001;18:515-6.
Rabbone I, Minuto N, Bonfanti R et al. Insulin pump failures in Italian 
children with Type 1 diabetes: retrospective 1-year cohort study Diabet 
Med 2017;34:621-4.
Raccah D, Sulmont V, Reznik Y et al Incremental value of continuous glucose 
monitoring when starting pump therapy in patients with poorly controlled 
type 1 diabetes: the RealTrend study. Diabetes Care 2009;32:2245–50.
REPOSE study group. Relative effectiveness of insulin pump treatment 
over multiple daily injections and structured education during flexible 
intensive insulin treatment for type 1 diabetes: cluster randomised trial 
(REPOSE) BMJ 2017;356:j1285.
Riddell MC, Gallen IW, Smart CE et al. Exercise management in type1 
diabetes: a consensus statement. Lancet Diabet Endocrinol 2017;5:377-90.
Rodrigues IA, Reid HA, Ismail K, Amiel SA. Indications and efficacy 
of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 
diabetes: a clinical audit in a specialist service. Diabetic Med 2005;22:842.
Ross P, Gray AR, Milburn J et al. Insulin pump-associated adverse 
events are common, but not associated with glycemic control, socio-
economic status, or pump/infusion set type. Acta Diabetol 2016;53:991-8.
Ruan Y, Thabit H, Leelarathna L et al. Variability of insulin 
requirements over 12 Weeks of closed-loop insulin delivery in adults 
with Type 1 Diabetes. Diabetes Care 2016;39:830-2.
Scheiner G, Sobel RJ, Smith DE, Pick AJ,  et al. Insulin pump therapy: 
guidelines for successful outcomes. Diabetes Educ 2009;35 S2:29S-41S.
Sharma D, Morrison G, Joseph F et al. The role of continuous 
subcutaneous insulin infusion therapy in patients with diabetic 
gastroparesis. Diabetologia 2011;54:2768–2770.
Slattery D, Amiel SA, Choudhary P. Optimal prandial timing of bolus 
insulin in diabetes management: a review. Diabet Med 2018;35:306-16.
Steineck I, Cederholm J, Eliasson B et al. Swedish National Diabetes 
Register. Insulin pump therapy, multiple daily injections, and 
cardiovascular mortality in 18,168 people with type 1 diabetes: 
observational study. BMJ 2015;350:h3234. 
Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in 
continuous subcutaneous insulin infusion using new formulas from 
a retrospective study of individuals with optimal glucose levels. J 
Diabetes Sci Technol 2010;4:1174-81.
Wilkinson J, McFann K, Chase HP. Factors affecting improved 
glycaemic control in youth using insulin pumps. Diabet Med 
2010;27:1174-7
Wizemann E, Renner R, Hepp K. Prospective evaluation of a 
standardized basal rate distribution for CSII in type 1 diabetes over 6 
months. Diabetologie und Stoffwechsel 2001;10:57.
Wong JC, Boyle C, DiMeglio LA et al. Evaluation of Pump 
Discontinuation and Associated Factors in the T1D Exchange Clinic 
Registry J Diabetes Sci Technol 2017;11:224-232.
029CLINICAL GUIDELINE 
BEST PRACTICE GUIDE
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) 
Basal rate testing protocol:
Basal rates should be tested where there is an indication 
that the rates are running too high, too low or to 
confirm a dawn phenomenon.
Basal rates can be tested at any of the four time blocks:
• Overnight
• Morning
• Afternoon
• Evening
When carrying out basal testing the user should bolus 
normally prior to the testing period, avoiding unusual 
meals or exercise, eliminating any snacks. For example if 
testing during the afternoon period the user would have 
breakfast with their normal bolus and then fast avoiding 
snacks and corrections. For 4 hours after breakfast blood 
glucose measurements should be taken 2 hourly during 
the day, unless using a glucose sensor or flash monitoring 
which provide continuous glucose data.
If at any time during the fasting period the patient 
experiences a hypoglycaemic episode or blood glucose 
levels go above 14.0mmol/l they should treat and 
abandon the test.
If there is a change in the blood glucose of more than 
1.5mmol/l during any time block then the basal for that 
time block is adjusted up or down by 0.05-0.1 unit per 
hour (or 10-20%) two hours prior to that glucose change.
Gold score for hypoglycaemia awareness
Please indicate on the scale how aware you are of when your hypos are commencing?
Always
1 2 3 4 5 6
Never
7
A score of ≥ 4 = impaired hypoglycaemia awareness
Adapted from: Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of 
hypoglycemia. Diabetes Care. 1994; 17(7):697-703
APPENDIX 1
APPENDIX 2
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Clarke hypoglycaemia awareness questionnaire
1. Check the category that best describes you:  
(check one only)
 © I always have symptoms when my blood sugar  
is low (A)
 © I sometimes have symptoms when my blood 
sugar is low (R)
 © I no longer have symptoms when my blood 
sugar is low (R)
2. Have you lost some of the symptoms that used to 
occur when your blood sugar was low?
 © Yes (R) 
 © No (A)
3. In the past six months how often have you had 
moderate hypoglycemia episodes?  
(Episodes where you might feel confused, disoriented, 
or lethargic and were unable to treat yourself)
 © Never (A) 
 © Once or twice (R) 
 © Every other month (R) 
 © Once a month (R) 
 © More than once a month (R)
4. In the past year how often have you had severe 
hypoglycemic episodes?  
(Episodes where you were unconscious or had a 
seizure and needed glucagon or intravenous glucose)
 © Never (A) 
 © 1 time (R) 
 © 2 times (R) 
 © 3 times (R)
 © 4 times (R) 
 © 5 times (R) 
 © 6 times (R) 
 © 7 times (R)
 © 8 times (R)
 © 9 times (R) 
 © 10 times (R) 
 © 11 times (R) 
 © 12 or more times (R)
5. How often in the last month have you had readings 
< 3.9 mmol/l with symptoms?
 © Never;  
 © 1 to 3 times; 
 © 1 time/week;  
 © 2 to 3 times/week;
 © 4 to 5 times/week; 
 © Almost daily 
6. How often in the last month have you had readings 
< 3.9 mmol/l without any symptoms?
 © Never;
 © 1 to 3 times;
 © 1 time/week; 
 © 2 to 3 times/week;
 © 4 to 5 times/week;
 © Almost daily 
7. How low does your blood sugar need to go before 
you feel symptoms?
 © 3.3-3.9 mmol/l (A)
 © 2.8-3.3 mmol/l (A) 
 © 2.2-2.8 mmol/l (R)
 © < 2.2 mmol/l (R)
8. To what extent can you tell by your symptoms that 
your blood sugar is low?
 © Never (R) 
 © Rarely (R) 
 © Sometimes (R) 
 © Often (A) 
 © Always (A)
Four or more R responses = impaired  
hypoglycaemia awareness 
Adapted from: Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, 
Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults 
with IDDM. A prospective study of hypoglycemic frequency and 
associated symptoms. Diabetes Care. 1995; 18(4):517-522
APPENDIX 3
R = answer to 5 ≤  
 answer to 6  
A = answer to 5 > 
 answer to 6
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